Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-synuclein degrader
- Development stage
- Preclinical
- Lead developer
- APRINOIA Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
APRINOIA Therapeutics is developing a small molecule alpha-synuclein (α-syn) degrader using Proteolysis-Targeting Chimera (PROTAC) technology for the treatment of alpha-synucleinopathies, including Parkinson's disease, Multiple System Atrophy, and Lewy Body Dementia. The degrader is designed to selectively target and remove pathological α-synuclein aggregates by recruiting them to the ubiquitin-proteasome system via an E3-ligase ligand, while sparing native, non-pathological proteins. The program has received funding and development support from the Michael J. Fox Foundation, Lundbeck, and AbbVie and is currently in the preclinical discovery stage.
- Other names
- α-synuclein PROTACα-SYN Degraderalpha-synuclein PROTAC degrader
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)
Beyond the preview
Go deeper on alpha-synuclein degrader.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-synuclein degrader.